← Back to Clinical Trials
Recruiting NCT05644548

NCT05644548 Retinal Vascular Manifestations in Patients With Common Internal Diseases on OCTA Tomography Angiography

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05644548
Status Recruiting
Phase
Sponsor Beijing Tongren Hospital
Condition Hypertension
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2022-03-01
Primary Completion 2023-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
No intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2022-03-01 with a primary completion date of 2023-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Hypertension, diabetes mellitus, and dyslipidemia are common internal diseases, and all diseases are atherosclerosis risk factors. Previous studies applied color fundus photography to analyze retinal vascular changes (including exudation, hemorrhage, neovascularization, etc.) in patients with hypertension or diabetes, but the examination results could not be quantified. This study intends to apply optical coherence tomography angiography (OCTA) to examine retinal vessels. This method has the following advantages: 1) It can quantify vascular changes, and 2) It is noninvasive and reproducible for patients' follow-up. This study was designed to investigate retinal vascular changes in patients with hypertension, diabetes, and dyslipidemia on OCTA. We will collect the patients' general information (gender, age), comorbidities, medications, blood lipids, blood glucose, carotid ultrasound, ankle-brachial index, ambulatory blood pressure monitoring, color fundus photography, and OCTA results. We will follow up with the patients for five years and conduct the mentioned examinations once a year. We will also investigate the correlation between systemic atherosclerosis (such as coronary artery stenosis, and carotid artery stenosis) and retinal vasculopathy in patients with these diseases.

Eligibility Criteria

Inclusion Criteria: * Patients with hypertension * Or patients with diabetes * Or patients with dyslipidemia * Agree to participate in this study Exclusion Criteria: * Patients with malignant tumors * Patients with autoimmune diseases * Patients with immunodeficiency disease * Disagree to participate in this study

Contact & Investigator

Central Contact

Yu He, MD

✉ bluelight323@126.com

📞 +861058268320

Frequently Asked Questions

Who can join the NCT05644548 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05644548 currently recruiting?

Yes, NCT05644548 is actively recruiting participants. Contact the research team at bluelight323@126.com for enrollment information.

Where is the NCT05644548 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT05644548 clinical trial?

NCT05644548 is sponsored by Beijing Tongren Hospital. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology